GuidelinesOther guideline
National Essential Medicine List Committee (NEMLC) Rapid Reviews
The National Essential Medicine List Committee (NEMLC) performs rapid reviews of the evidence for proposed treatment options for COVID-19 disease. The Committee has evaluated evidence for: Interferon Ivermectin for prophylaxis of COVID-19 Ivermectin for treatment of COVID-19 Hydroxychloroquine/ chloroquine IV Immunoglobulin Tocilizumab for the treatment of COVID-19 Lopinavir/ Ritonavir Azithromyc
The National Essential Medicine List Committee (NEMLC) performs rapid reviews of the evidence for proposed treatment options for COVID-19 disease.
The Committee has evaluated evidence for:
- Interferon
- Ivermectin for prophylaxis of COVID-19
- Ivermectin for treatment of COVID-19
- Hydroxychloroquine/ chloroquine
- IV Immunoglobulin
- Tocilizumab for the treatment of COVID-19
- Lopinavir/ Ritonavir
- Azithromycin
- BCG for prophylaxis of COVID-19
- Convalescent Plasma
- Heparin for VTE
- Chloroquine prophylaxis
- Inhaled Corticosteroids
- Remdesivir
- Favipiravir
- Colchicine
- Mucolytics
- Baricitinib
- Rivaroxaban
- Doxycycline
- Fluvoxamine
- NSAIDs
- Nirmatrelvir-ritonavir
- Antiplatelets
To view all the rapid reviews, click here
To read more on the NEMLC and the review process, click here
To view the NEMLC Rapid Review template, click here